Table of Contents Author Guidelines Submit a Manuscript
International Journal of Vascular Medicine
Volume 2012, Article ID 453264, 11 pages
http://dx.doi.org/10.1155/2012/453264
Review Article

The Effect of Antihypertensive Drugs on Endothelial Function as Assessed by Flow-Mediated Vasodilation in Hypertensive Patients

1Department of Clinical Laboratory Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-City, Tochigi 329-0498, Japan
2Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-City, Tochigi 329-0498, Japan

Received 11 September 2011; Revised 22 November 2011; Accepted 23 December 2011

Academic Editor: Tomoki Hashimoto

Copyright © 2012 Michiaki Miyamoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Deanfield, J. P. Halcox, and T. J. Rabelink, “Endothelial function and dysfunction: testing and clinical relevance,” Circulation, vol. 115, no. 10, pp. 1285–1295, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. U. Landmesser and H. Drexler, “Endothelial function and hypertension,” Current Opinion in Cardiology, vol. 22, no. 4, pp. 316–320, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Nadar, A. D. Blann, and G. Y. H. Lip, “Endothelial dysfunction: methods of assessment and application to hypertension,” Current Pharmaceutical Design, vol. 10, no. 29, pp. 3591–3605, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. A. S. de Vriese, T. J. Verbeuren, J. van de Voorde, N. H. Lameire, and P. M. Vanhoutte, “Endothelial dysfunction in diabetes,” British Journal of Pharmacology, vol. 130, no. 5, pp. 963–974, 2000. View at Google Scholar · View at Scopus
  5. J. Xu and M. H. Zou, “Molecular insights and therapeutic targets for diabetic endothelial dysfunction,” Circulation, vol. 120, no. 13, pp. 1266–1286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Perticone, R. Ceravolo, A. Pujia et al., “Prognostic significance of endothelial dysfunction in hypertensive patients,” Circulation, vol. 104, no. 2, pp. 191–196, 2001. View at Google Scholar · View at Scopus
  8. M. G. Modena, L. Bonetti, F. Coppi, F. Bursi, and R. Rossi, “Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women,” Journal of the American College of Cardiology, vol. 40, no. 3, pp. 505–510, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. M. C. Corretti, T. J. Anderson, E. J. Benjamin et al., “Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force,” Journal of the American College of Cardiology, vol. 39, no. 2, pp. 257–265, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. D. S. Celermajer, K. E. Sorensen, V. M. Gooch et al., “Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis,” The Lancet, vol. 340, no. 8828, pp. 1111–1115, 1992. View at Publisher · View at Google Scholar · View at Scopus
  11. J. A. Whitworth, World Health Organization, and International Society of Hypertension Writing Group, “2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension,” Journal of Hypertension, vol. 21, no. 11, pp. 1983–1992, 2003. View at Google Scholar
  12. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report,” The Journal of the American Medical Association, vol. 289, no. 19, pp. 2560–2572, 2003. View at Google Scholar
  13. E. J. Benjamin, M. G. Larson, M. J. Keyes et al., “Clinical correlates and heritability of flow-mediated dilation in the community: the framingham heart study,” Circulation, vol. 109, no. 5, pp. 613–619, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Juonala, J. S. A. Viikari, T. Laitinen et al., “Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young finns study,” Circulation, vol. 110, no. 18, pp. 2918–2923, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Zaza, L. K. Wright-De Agüero, P. A. Briss et al., “Data collection instrument and procedure for systematic reviews in the Guide to Community Preventive Services,” American Journal of Preventive Medicine, vol. 18, no. 1, supplement, pp. 44–74, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. M. L. Muiesan, M. Salvetti, C. Monteduro et al., “Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension,” Hypertension, vol. 33, no. 1, part 2, pp. 575–580, 1999. View at Google Scholar · View at Scopus
  17. D. Yavuz, M. Koç, A. Toprak et al., “Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 4, no. 3, pp. 197–203, 2003. View at Google Scholar
  18. D. C. Felmeden, C. G. C. Spencer, N. A. Y. Chung et al., “Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]),” American Journal of Cardiology, vol. 92, no. 4, pp. 400–405, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Tezcan, D. Yavuz, A. Toprak et al., “Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 4, no. 2, pp. 119–123, 2003. View at Google Scholar · View at Scopus
  20. M. Munakata, A. Aihara, T. Nunokawa et al., “The influence of one-year treatment by angiotensin converting enzyme inhibitor on baroreflex sensitivity and flow-mediated vasodilation of the brachial artery in essential hypertension—comparison with calcium channel blockers,” Clinical and Experimental Hypertension, vol. 25, no. 3, pp. 169–181, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Ghiadoni, A. Magagna, D. Versari et al., “Different effect of antihypertensive drugs on conduit artery endothelial function,” Hypertension, vol. 41, no. 6, pp. 1281–1286, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. K. K. Koh, M. J. Quon, S. H. Han et al., “Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients,” Circulation, vol. 110, no. 24, pp. 3687–3692, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. K. K. Koh, S. H. Han, W. J. Chung et al., “Comparison of effects of Losartan, Irbesartan, and Candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension,” American Journal of Cardiology, vol. 93, no. 11, pp. 1432–1435, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Morimoto, Y. Yano, K. Maki, and K. Sawada, “Renal and vascular protective effects of telmisartan in patients with essential hypertension,” Hypertension Research, vol. 29, no. 8, pp. 567–572, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. L. A. Souza-Barbosa, S. E. Ferreira-Melo, S. Ubaid-Girioli, E. Arantes Nogueira, J. C. Yugar-Toledo, and H. Moreno Jr., “Endothelial vascular function in hypertensive patients after renin-angiotensin system blockade,” The Journal of Clinical Hypertension, vol. 8, no. 11, pp. 803–811, 2006. View at Google Scholar · View at Scopus
  26. E. R. Mohler III, D. Herrington, P. Ouyang et al., “A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure,” The Journal of Clinical Hypertension, vol. 8, no. 10, pp. 692–698, 2006. View at Google Scholar
  27. T. Oshima, R. Ozono, Y. Yano et al., “Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension,” Hypertension Research, vol. 28, no. 11, pp. 889–894, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Ghiadoni, D. Versari, A. Magagna et al., “Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients,” Journal of Hypertension, vol. 25, no. 2, pp. 361–366, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. A. F. Pasini, U. Garbin, M. C. Nava et al., “Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients,” American Journal of Hypertension, vol. 20, no. 4, pp. 443–450, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. N. H. Buus, C. G. Jørgensen, M. J. Mulvany, and K. E. Sørensen, “Large and small artery endothelial function in patients with essential hypertension—effect of ACE inhibition and beta-blockade,” Blood Pressure, vol. 16, no. 2, pp. 106–113, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. R. A. Benndorf, D. Appel, R. Maas, E. Schwedhelm, U. O. Wenzel, and R. H. Böger, “Telmisartan improves endothelial function in patients with essential hypertension,” Journal of Cardiovascular Pharmacology, vol. 50, no. 4, pp. 367–371, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. A. J. Flammer, F. Hermann, P. Wiesli et al., “Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension,” Journal of Hypertension, vol. 25, no. 4, pp. 785–791, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Morimoto, Y. Yano, K. Maki, and T. Iwasaka, “Renal and vascular protective effects of cilnidipine in patients with essential hypertension,” Journal of Hypertension, vol. 25, no. 10, pp. 2178–2183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Morimoto, K. Maki, Y. Aota, T. Sakuma, and T. Iwasaka, “Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function,” Hypertension Research, vol. 31, no. 8, pp. 1603–1610, 2008. View at Google Scholar · View at Scopus
  35. Y. Hirooka, Y. Kimura, Y. Sagara, K. Ito, and K. Sunagawa, “Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension,” Clinical and Experimental Hypertension, vol. 30, no. 3-4, pp. 267–276, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Korkmaz, I. Karaca, M. Koc, O. Onalan, M. Yilmaz, and M. N. Bilen, “Early effects of treatment with nebivolol and quinapril on endothelial function in patients with hypertension,” Endothelium, vol. 15, no. 3, pp. 149–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Yamada, H. Tomiyama, C. Matsumoto, M. Yoshida, K. Shiina, and A. Yamashina, “Effects of azelnidipine on the autonomic functions and its influence on arterial stiffness and endothelial functions,” Journal of Cardiology, vol. 51, no. 2, pp. 114–120, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Farkas, E. Fábián, and L. Nagy, “Quinapril improves endothelial function in postmenopausal hypertensive patients,” Kidney and Blood Pressure Research, vol. 31, no. 4, pp. 226–233, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Rossi, A. Nuzzo, G. Origliani, and M. G. Modena, “Metabolic syndrome affects cardiovascular risk profile and response to treatment in hypertensive postmenopausal women,” Hypertension, vol. 52, no. 5, pp. 865–875, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. J. R. Jennings, M. F. Muldoon, J. Price, I. C. Christie, and C. C. Meltzer, “Cerebrovascular support for cognitive processing in hypertensive patients is altered by blood pressure treatment,” Hypertension, vol. 52, no. 1, pp. 65–71, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. A. F. Pasini, U. Garbin, C. Stranieri et al., “Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients,” American Journal of Hypertension, vol. 21, no. 11, pp. 1251–1257, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Kosch, A. Levers, D. Lang et al., “A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension,” Nephrology Dialysis Transplantation, vol. 23, no. 7, pp. 2280–2285, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Merchant, C. D. Searles, A. Pandian et al., “Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function,” The Journal of Clinical Hypertension, vol. 11, no. 12, pp. 720–725, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. D. Jung, W. Kim, S. H. Park et al., “The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension,” Korean Circulation Journal, vol. 39, no. 5, pp. 180–184, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Ubaid-Girioli, L. A. de Souza, J. C. Yugar-Toledo et al., “Aldosterone excess or escape: treating resistant hypertension,” The Journal of Clinical Hypertension, vol. 11, no. 5, pp. 245–252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Yamanari, K. Nakamura, D. Miura, S. Yamanari, and T. Ohe, “Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin ii receptor-blocker: effects on endothelial function, inflammation, and oxidative stress,” Clinical and Experimental Hypertension, vol. 31, no. 7, pp. 585–594, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Perrone-Filardi, L. Corrado, G. Brevetti et al., “Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease,” The Journal of Clinical Hypertension, vol. 11, no. 5, pp. 260–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Ghiadoni, A. Magagna, I. Kardasz, S. Taddei, and A. Salvetti, “Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients,” American Journal of Hypertension, vol. 22, no. 5, pp. 506–512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. S. A. Brandão, M. C. Izar, S. M. Fischer et al., “Early increase in autoantibodies against human oxidized low-density lipoprotein in hypertensive patients after blood pressure control,” American Journal of Hypertension, vol. 23, no. 2, pp. 208–214, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. M. I. Yilmaz, J. J. Carrero, J. L. Martín-Ventura et al., “Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 7, pp. 1174–1181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Wago, T. Yoshimoto, I. Akaza et al., “Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan,” Hypertension Research, vol. 33, no. 8, pp. 796–801, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Takiguchi, M. Ayaori, H. Uto-Kondo et al., “Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase,” Hypertension Research, vol. 34, no. 6, pp. 686–692, 2011. View at Google Scholar
  53. K. S. Heffernan, R. Suryadevara, E. A. Patvardhan, P. Mooney, R. H. Karas, and J. T. Kuvin, “Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension,” Clinical Cardiology, vol. 34, no. 1, pp. 39–44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. S. A. Hunt, D. W. Baker, M. H. Chin et al., “ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure),” Journal of the American College of Cardiology, vol. 38, no. 7, pp. 2101–2113, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. B. M. Brenner, M. E. Cooper, D. de Zeeuw et al., “Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy,” The New England Journal of Medicine, vol. 345, no. 12, pp. 861–869, 2001. View at Google Scholar
  56. UK Prospective Diabetes Study Group, “Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39,” British Medical Journal, vol. 317, no. 7160, pp. 713–720, 1998. View at Google Scholar
  57. F. Turnbull and Blood Pressure Lowering Treatment Trialists' Collaboration, “Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials,” The Lancet, vol. 362, no. 9395, pp. 1527–1535, 2003. View at Google Scholar
  58. E. Braunwald, E. M. Antman, J. W. Beasley et al., “ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—aummary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina),” Journal of the American College of Cardiology, vol. 40, no. 7, pp. 1366–1374, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. L. M. Prisant, “Nebivolol: pharmacologic profile of an ultraselective, vasodilatory β,” Journal of Clinical Pharmacology, vol. 48, no. 2, pp. 225–239, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. M. L. Muiesan, M. Salvetti, A. Paini et al., “Prognostic role of flow-mediated dilatation of the brachial artery in hypertensive patients,” Journal of Hypertension, vol. 26, no. 8, pp. 1612–1618, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. A. E. Donald, J. P. Halcox, M. Charakida et al., “Methodological approaches to optimize reproducibility and power in clinical studies of flow-mediated dilation,” Journal of the American College of Cardiology, vol. 51, no. 20, pp. 1959–1964, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Ghiadoni, D. Versari, C. Giannarelli, F. Faita, and S. Taddei, “Non-invasive diagnostic tools for investigating endothelial dysfunction,” Current Pharmaceutical Design, vol. 14, no. 35, pp. 3715–3722, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Charakida, S. Masi, T. F. Lüscher, J. J. P. Kastelein, and J. E. Deanfield, “Assessment of atherosclerosis: the role of flow-mediated dilatation,” European Heart Journal, vol. 31, no. 23, pp. 2854–2861, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. T. Asahara, T. Murohara, A. Sullivan et al., “Isolation of putative progenitor endothelial cells for angiogenesis,” Science, vol. 275, no. 5302, pp. 964–967, 1997. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Woywodt, F. H. Bahlmann, K. de Groot, H. Haller, and M. Haubitz, “Circulating endothelial cells: life, death, detachment and repair of the endothelial cell layer,” Nephrology Dialysis Transplantation, vol. 17, no. 10, pp. 1728–1730, 2002. View at Google Scholar · View at Scopus
  66. P. N. Seshiah, D. S. Weber, P. Rocic, L. Valppu, Y. Taniyama, and K. K. Griendling, “Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators,” Circulation Research, vol. 91, no. 5, pp. 406–413, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. K. K. Griendling, D. Sorescu, and M. Ushio-Fukai, “NAD(P)H oxidase: role in cardiovascular biology and disease,” Circulation Research, vol. 86, no. 5, pp. 494–501, 2000. View at Google Scholar · View at Scopus
  68. C. I. Johnston, “Angiotensin receptor antagonists: focus on losartan,” The Lancet, vol. 346, no. 8987, pp. 1403–1407, 1995. View at Google Scholar · View at Scopus
  69. T. L. Goodfriend, M. E. Elliott, and K. J. Catt, “Angiotensin receptors and their antagonists,” The New England Journal of Medicine, vol. 334, no. 25, pp. 1649–1654, 1996. View at Google Scholar · View at Scopus
  70. A. Warnholtz, G. Nickenig, E. Schulz et al., “Increased NADH-oxidase-mediated superoxide production. In the early stages of atherosclerosis evidence for involvement of the renin-angiotensin system,” Circulation, vol. 99, no. 15, pp. 2027–2033, 1999. View at Google Scholar · View at Scopus
  71. A. Salameh, G. Schomecker, K. Breitkopf, S. Dhein, and W. Klaus, “The effect of the calcium-antagonist nitrendipine on intracellular calcium concentration in endothelial cells,” British Journal of Pharmacology, vol. 118, no. 8, pp. 1899–1904, 1996. View at Google Scholar · View at Scopus
  72. R. Berkels, G. Egink, T. A. Marsen, H. Bartels, R. Roesen, and W. Klaus, “Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms,” Hypertension, vol. 37, no. 2, pp. 240–245, 2001. View at Google Scholar · View at Scopus
  73. A. Gomes, D. Costa, J. L. F. C. Lima, and E. Fernandes, “Antioxidant activity of β-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species?” Bioorganic and Medicinal Chemistry, vol. 14, no. 13, pp. 4568–4577, 2006. View at Publisher · View at Google Scholar · View at Scopus